Market Overview

UPDATE: Credit Suisse Upgrades Medtronic to Outperform on Growth Outlook

Share:
Related MDT
Medtronic Acquires Medina Medical for Initial Payment of $150M, Plus Milestones
Medtronic Study Detects Gene Associated with Sudden Cardiac Death
Medtronic Rises Ahead Of Earnings On Higher Target (Investor's Business Daily)

Credit Suisse upgraded Medtronic (NYSE: MDT) from Neutral to Outperform and raised the price target from $47.00 to $50.00.

Credit Suisse noted, "MDT's F2H13 & F14 growth aspirations indicate increased confidence that the last 2 quarters of ~5% WW CC growth represent sustainable improvement relative to the flattish top-line growth reported in FY11 & FY12 and further suggest that the growth-oriented acquisitions (Peak, Salient, KH) and increased emerging markets focus that have taken place during CEO Omar Ishrak's early tenure with the company are moving MDT in the right strategic direction."

Medtronic closed at $43.94 on Wednesday.

Latest Ratings for MDT

DateFirmActionFromTo
Sep 2015Cowen & CompanyMaintainsOutperform
Aug 2015Credit SuisseAssumesOutperform
Jul 2015BTIG ResearchUpgradesNeutralBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (MDT)

Get Benzinga's Newsletters